-
December 18, 2013 Lupin launches Generic Trizivir® Tablets
-
December 12, 2013 Lupin launches Generic Cymbalta® Delayed-Release Capsules 20 mg, 30 mg and 60 mg strengths in the US
-
December 10, 2013 Lupin Receives FDA Approval for Generic Trizivir® Tablets
-
December 6, 2013 Lupin launches Generic Trilipix® Delayed-Release Capsules 45 mg & 135 mg in the US
-
November 11, 2013 Lupin launches Generic Aciphex® Delayed-Release Tablets, 20 mg in the US
-
October 18, 2013 Lupin Receives International Sustainability Rating Standard (ISRS) Certification First Pharmaceutical Company globally to adopt ISRS, 8th Edition standard
-
October 3, 2013 Lupin launches Generic ZYMAXID™ Ophthalmic solution in the US
-
September 23, 2013 Lupin Expands US Pediatric Brands Portfolio Inks Strategic Agreement to Promote Locoid® Lotion to US Pediatricians
-
September 16, 2013 Lupin Receives FDA Approval for Generic Ambien CR® Extended-release Tablets
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications